About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Analysis of C. difficile Isolated from Stools of Patients Enrolled in a Phase II Clinical Trial of Ridinilazole (SMT 19969) Analysis of C. difficile Isolated from Stools of Patients Enrolled in a Phase II Clinical Trial of Ridinilazole (SMT 19969) June 20, 2016 By CKD Digital
Analysis of C. difficile Isolated from Stools of Patients Enrolled in a Phase II Clinical Trial of Ridinilazole (SMT 19969)
Analysis of C. difficile Isolated from Stools of Patients Enrolled in a Phase II Clinical Trial of Ridinilazole (SMT 19969) June 20, 2016 By CKD Digital